- Home
- STTK vs FBLG Comparison
STTK vs FBLG Comparison
Compare STTK & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FBLG
- Stock Information
- Founded
- STTK 2016
- FBLG 2021
- Country
- STTK United States
- FBLG United States
- Employees
- STTK N/A
- FBLG N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FBLG
- Sector
- STTK Health Care
- FBLG
- Exchange
- STTK Nasdaq
- FBLG NYSE
- Market Cap
- STTK 38.4M
- FBLG 37.1M
- IPO Year
- STTK 2020
- FBLG 2024
- Fundamental
- Price
- STTK $0.77
- FBLG $0.63
- Analyst Decision
- STTK Hold
- FBLG Strong Buy
- Analyst Count
- STTK 4
- FBLG 4
- Target Price
- STTK $3.00
- FBLG $13.00
- AVG Volume (30 Days)
- STTK 229.3K
- FBLG 480.7K
- Earning Date
- STTK 08-04-2025
- FBLG 08-11-2025
- Dividend Yield
- STTK N/A
- FBLG N/A
- EPS Growth
- STTK N/A
- FBLG N/A
- EPS
- STTK N/A
- FBLG N/A
- Revenue
- STTK $4,606,000.00
- FBLG N/A
- Revenue This Year
- STTK N/A
- FBLG N/A
- Revenue Next Year
- STTK N/A
- FBLG N/A
- P/E Ratio
- STTK N/A
- FBLG N/A
- Revenue Growth
- STTK 69.65
- FBLG N/A
- 52 Week Low
- STTK $0.69
- FBLG $0.58
- 52 Week High
- STTK $4.51
- FBLG $5.54
- Technical
- Relative Strength Index (RSI)
- STTK 41.85
- FBLG 42.37
- Support Level
- STTK $0.73
- FBLG $0.61
- Resistance Level
- STTK $0.92
- FBLG $0.72
- Average True Range (ATR)
- STTK 0.07
- FBLG 0.06
- MACD
- STTK 0.01
- FBLG 0.00
- Stochastic Oscillator
- STTK 20.80
- FBLG 35.48
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.